Competing interests
K.E.H., G.R., L.H.F. and J.N.P. are employees and stockholders of Roche/Genentech. T.J.P. has consulted for Illumina, Merck, AstraZeneca, PACT Pharma, Chrysalis Biomedical Advisors and the Canadian Pension Plan Investment Board (compensated); and receives research support (institutional) from Roche/Genentech. B.G. reports travel and accommodation expenses for attendance at a Roche-sponsored advisory board for atezolizumab. L.V.M. has provided consultation for Bayer, BMS, Tesaro and Illumina. T.T. reports consultancy fees from Roche/Genentech for advisory board attendance and previous protocol management activities from POETIC Data and Coordinating Center outside of the submitted work. All other authors have no competing interests.